Polybrominated diphenyl ethers (PBDEs) are persistent and bioaccumulative flame retardants, which are found in rising concentrations in human tissues. They are of concern for human health because animal studies have shown that they possess the potential to be developmentally toxic.

**Background:** Polybrominated diphenyl ethers (PBDEs) are persistent and bioaccumulative flame retardants, which are found in rising concentrations in human tissues. They are of concern for human health because animal studies have shown that they possess the potential to be developmentally toxic.

**Objective:** Because there is little knowledge of the effects of PBDEs on human brain cells, we investigated their toxic potential for human neural development in vitro. Moreover, we studied the involvement of thyroid hormone (TH) disruption in the effects caused by PBDEs.

**Methods:** We used the two PBDE congeners BDE-47 and BDE-99 (0.1–10 μM), which are most prominent in human tissues. As a model of neural development, we employed primary fetal human neural progenitor cells (hNPCs), which are cultured as neurospheres and mimic basic processes of brain development in vitro: proliferation, migration, and differentiation.

**Results:** PBDEs do not disturb hNPC proliferation but decrease migration distance of hNPCs. Moreover, they cause a reduction of differentiation into neurons and oligodendrocytes. Simultaneous exposure with the TH receptor (THR) agonist triiodothyronine (T3) and the THR antagonist NH-3 rescues these effects on migration and differentiation, whereas the THR antagonist NH-3 does not exert an additive effect.

**Conclusion:** PBDEs disturb development of hNPCs in vitro via endocrine disruption of cellular TH signaling at concentrations that might be of relevance for human exposure.

**Keywords:** brain, development, human, in vitro, neural, neural progenitor cells, neurosphere, PBDE, toxicity. *Environ Health Perspect* 118:572–578 (2010). doi:10.1289/ehp.0901435 [Online 7 December 2009]

Polybrominated diphenyl ethers (PBDEs) are persistent and bioaccumulative flame retardants that are of concern because they are ubiquitous, are potentially toxic, and have been found at rapidly rising levels in humans during the past few decades [reviewed by Costa et al. (2008)]. PBDEs are widely used by industry as flame retardants in, for example, textiles, electrics, plastics, and furniture. Over time, PBDEs diffuse out of the matrix and bioaccumulate in the environment (Scherect et al. 2006). Furthermore, these chemicals are primarily indoor pollutants and are found at high levels in household dust and other home and workplace environmental samples (Scherect et al. 2005a; Stapleton et al. 2005). The abundance in household dust especially causes high exposure of toddlers and children (Fischer et al. 2006). PBDEs also accumulate in the human body; very high levels have recently been found in milk (Kalantzi et al. 2004; Schchter et al. 2003, 2005b), blood including fetal blood (Mazdai et al. 2003; Morland et al. 2005; Schchter et al. 2005b; Sjodin et al. 2004), placenta (Doucet et al. 2009), and adipose tissue (Johnson-Restrepo et al. 2005; She et al. 2002). Although levels of dioxins, dibenzofurans, and polychlorinated biphenyls (PCBs) have been declining in human tissues, PBDE levels have increased substantially during the past two decades (Scherect et al. 2005b; Sjodin et al. 2004).

The high levels of PBDEs in the human population, especially in infants and toddlers, are of vast concern because these compounds are chemically similar to PCBs and have been shown to be developmentally neurotoxic in rodents. Various PBDE congeners cause behavioral alterations, such as hyperactivity, and disrupt performance in learning and memory tests in perinatally exposed mice and rats (reviewed by Costa et al. 2008).

Despite extensive information on human exposure and body burden, there is no information on possible neurodevelopmental adverse effects in humans from PBDE exposure. Therefore, any potential risk for adverse nervous system effects in humans has to be extrapolated from animal studies (Costa et al. 2008). To facilitate PBDE hazard assessment for humans, we investigated the impact of PBDEs on human neurodevelopment in vitro and studied the mechanisms underlying these changes. For these analyses, we used two of the most prominent congeners found in human tissues, the tetrabrominated congener BDE-47 and the pentabrominated congener BDE-99 [reviewed by Costa et al. (2008)]. We investigated the effects of these PBDEs on the developmental neurotoxicity (DNT)—specific end points proliferation, migration, and differentiation, as well as cell viability, in a human model that mimics brain development in vitro (Fritsche et al. 2005; Mors et al. 2007, 2009, 2010). Furthermore, we performed competition studies with the thyroid hormone (TH) receptor (THR) agonist triiodothyronine (T3) and the THR antagonist NH-3, or [4-(4-Hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)-3,5-dimethyl]acetic acid, to investigate the involvement of TH disruption in the observed effects by PBDEs.

**Materials and Methods**

Chemicals. BDE-47 and BDE-99 were a kind gift from U. Strähle from the Karlsruhe Institute of Technology and were diluted in dimethyl sulfoxide (DMSO) at stock concentrations of 1, 10, and 100 mM (purity of both PBDEs were 98.88%). 14C-BDE-47 (55 μCi/mg, stated purity > 96%) was a kind gift from K. Crofton from the U.S. Environmental Protection Agency and was diluted in toluene at a stock concentration of 131 mM. T3 (Sigma-Aldrich, Munich, Germany) and NH-3 (Nguyen et al. 2002) were diluted in ethanol (300 mM) and DMSO (1 mM), respectively.

**Cell culture.** Normal human neural progenitor cells (hNPCs; Lonza Verviers SPRL, Verviers, Belgium) generated from gestational week 16 were cultured as free-floating neurospheres in proliferation medium (Dulbecco’s modified Eagle medium and Hams F12 (3:1))
supplemented with B27 (Invitrogen GmBH, Karlsruhe, Germany), 20 ng/mL epidermal growth factor (EGF; Biosource, Karlsruhe, Germany), 20 ng/mL recombinant human fibroblast growth factor (rhFGF; R&D Systems, Wiesbaden-Nordenstadt, Germany), and penicillin and streptomycin (1:100 vol/ vol; Invitrogen) at 37 °C with 7.5% CO₂ as previously described (Moors et al. 2007, 2009). Differentiation was initiated by growth factor withdrawal in differentiation medium [Dulbecco’s modified Eagle medium and Hams F12 (3:1) supplemented with N2 (Invitrogen)] and plating onto a poly-d-lysine/ laminin matrix.

**Chemical exposure.** For viability, migration, and differentiation analyses, neurospheres were preincubated for 1 week with PBDEs (0.1, 1, or 10 µM) in proliferation medium; afterward, differentiation was initiated and spheres differentiated with the same concentrations of PBDEs in differentiation medium for 48 hr (migration measurements) or 7 days (differentiation analyses). This treatment scheme is supposed to imitate exposure of fetal cells during expansion and differentiation in utero. For proliferation analyses, neurospheres were treated for 2 weeks with PBDEs (0.1, 1, or 10 µM) in proliferation medium. For cotreatment with T₃ or NH-3, spheres were incubated for 48 hr (migration) or 7 days (differentiation) with the indicated concentrations after differentiation was initiated.

**Viability assay.** Cell viability was measured using the alamarBlue assay (CellTiter-Blue assay, Promega, Madison, WI, USA), which measures mitochondrial reductase activity, and the CytoTox-ONE assay (Promega), which determines lactate dehydrogenase release, according to the manufacturer’s description. In addition, to determine whether PBDEs cause cell death in differentiating cells in the migration area, cells were incubated for 5 min with 0.1% trypsin blue (Sigma-Aldrich). Afterwards, dead cells were counted manually in relation to the total number of nuclei in the field.

**RNA preparation and reverse-transcriptase polymerase chain reaction.** Total RNA was prepared from five differentiated neurospheres either untreated or treated with 10 µM PBDE using the Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA, USA). Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was performed as previously described (Fritsche et al. 2007). Primer sequences for nestin are as follows: forward GGACT (reverse) and AGGGAAGTTGGGCTCA CAGCTGGCGCACCTCAAGATG (for annealing) and AGGGAAGTTGGGCTCA CAGCTGGCGCACCTCAAGATG (reverse). Primer sequences for β-actin are CCCCCAGGACACCGGCGGT (forward) and GGTCACTCTTCTGCGGTT GCCCTTTGGGT (reverse).

**Calcium imaging.** We treated neurospheres for 1 week with 10 µM BDE-47 or BDE-99. Subsequently, differentiation was induced under ongoing PBDE exposure. After 24 hr, ratiometric calcium imaging was performed using a wide-field epifluorescence system (TILL Photonics, Martinsried, Germany) attached to an upright microscope (Axioskop; Zeiss, Oberkochen, Germany) with a 40× water-immersion objective (0.8 numerical aperture; Olympus Europe, Hamburg, Germany). Excitation was generated by a monochromator; emission was detected by a CCD camera (imago super-VGA: TILL). Cells were passively loaded by addition of the calcium indicator dye fura-2-acetoxymethyl ester (15 µM; Tefabs, Invitrogen) for 90 min. Fura-2 fluorescence was alternately excited at the isosbestic point (357 nm) and at the calcium-sensitive wavelength (380 nm), and the ratio of fluorescence emission (F357/F380) in regions of interest positioned around cell somata was calculated. Adenosine triphosphate (ATP) and acetylcholine (ACh) were puff-applied using a Picospritzer II (General Valve/ Parker Hanifin, Felsin/Heilbronn, Germany) coupled to standard micropipettes with a tip diameter of around 1.5 µm (Hilgenberg, Waldkappel, Germany) placed at a distance of approximately 10–20 µm above the cell layer. Data analysis was performed using TILLVision and IgorPro software (Wavemetrics, Lake Oswego, OR, USA). To determine effects on [Ca²⁺], we used the normalized F357/F380 ratio for puf application. Any change in the normalized ratios to ≥ 1.2 was considered an increase and was used for further data analysis.

**Statistics.** For multifactor analyses of variance in combination with the Bonferroni post hoc test was used. Student’s t-test was used for two group comparison. The significance value was set at p ≤ 0.05.

**Results**

**Effects of PBDEs on hNPC viability.** To determine viability of cells, we preincubated spheres for 7 days with different concentrations of BDE-47 or BDE-99 under proliferating conditions followed by further differentiation in presence of PBDEs for 7 days or for 14 days as proliferating spheres. Neither mitochondrial activity nor release of lactate dehydrogenase changed significantly compared with the DMSO controls. Additionally, visual inspection of migration areas after staining with 0.1% trypan blue indicated that in all samples the number of dead or damaged cells was <1% (data not shown). Thus, BDE-47 or BDE-99 did not cause cytotoxicity of

Environmental Health Perspectives • VOLUME 118 • NUMBER 4 • April 2010

573
hNPC [see Supplemental Material, Figure 1 (doi:10.1289/ehp.0901435)].

**Effects of PBDEs on hNPC proliferation.** For assessment of hNPC proliferation, we cultured neurospheres with and without PBDEs (0.1–1 µM) for 2 weeks. We determined increases in cell number by measuring sphere diameter (Moors et al. 2009). In contrast to the negative control without mitogens, PBDEs did not impair sphere growth over time [see Supplemental Material, Figure 2 (doi:10.1289/ehp.0901435)].

**Effects of PBDEs on hNPC migration.** To measure migration, we determined the distance between the sphere edge and the farthest migrated cells 48 hr after plating. The solvent controls migrated 942.1 ± 42.9 µm within 48 hr, whereas BDE-47–treated hNPCs migrated 838.9 ± 11.6 µm (89.0 ± 1.2% of control; 0.1 µM), 755.3 ± 20.7 µm (80.2 ± 2.2% of control; 1 µM), and 600.7 ± 21.4 µm (70.1 ± 2.3% of control; 10 µM) and BDE-99 exposed cells migrated 781.9 ± 14.8 µm (83.0 ± 1.6% of control; 0.1 µM), 674.5 ± 24.4 µm (71.6 ± 2.6% of control; 1 µM), and 609.6 ± 33.6 µm (64.7 ± 3.6% of control; 10 µM). These data show that PBDEs reduce hNPC migration in a concentration-dependent manner (Figure 1).

**Effects of PBDEs on hNPC differentiation.** To investigate the influence of PBDEs on differentiation of hNPCs, we preincubated spheres with PBDEs for 7 days under proliferating conditions. After 7 additional days of differentiation under PBDE exposure, we performed immunocytochemical staining for β(III)tubulin (neurons) and O4 (oligodendrocytes; Figure 2). The number of control and PBDE-exposed nuclei in the differentiation zones, visualized with Hoechst, did not differ [see Supplemental Material, Figure 3 (doi:10.1289/ehp.0901435)]. Manual counting of immunopositive cells under blinded conditions revealed that 26.6 ± 3.2% of the control cells were positive for β(III)tubulin, whereas PBDE exposure reduced immunopositive cells to 21.6 ± 1.8% (0.1 µM), 16.8 ± 2.1% (1 µM), and 13.3 ± 3.0% (10 µM) for BDE-47 and to 16.3 ± 1.5% (0.1 µM), 13.4 ± 0.5% (1 µM), and 8.3 ± 2.0% (10 µM) for BDE-99. The effects of PBDE exposure on oligodendrogenesis were stronger than on neurogenesis. Although 5.7 ± 0.8% of all differentiated cells were immunoreactive for O4 after 7 days of differentiation in the control cultures, in the BDE-47–exposed groups only 4.5 ± 0.5% (0.1 µM), 3.9 ± 0.6% (1 µM), and 2.8 ± 0.6% (10 µM) stained O4 positive, and in the BDE-99–treated cells 4.5 ± 0.6% (0.1 µM), 2.7 ± 0.6% (1 µM), and 0.4 ± 0.4% (10 µM). Thus, PBDEs inhibit neural differentiation of hNPCs in a concentration-dependent manner.

To determine whether PBDEs lead to cell type–specific inhibition of migration, causing cells to remain within the sphere, or whether PBDEs lead to an actual delay in differentiation, we performed real-time RT-PCR analyses of the entire spheres with nestin, a marker of undifferentiated progenitor cells. Control spheres displayed only weak expression of nestin after 7 days of differentiation. In contrast, BDE-47 and BDE-99 increased nestin expression 4- and 5-fold, showing that PBDEs delay differentiation of hNPCs (Figure 3B).

**PBDEs interfere with THR signal transduction.** To study involvement of endocrine disruption in the observed PBDE effects, we employed the THR agonist T3 and the antagonist NH-3. After initiating differentiation, we exposed the spheres to 10 µM BDE-47 or BDE-99 with or without 3 nM T3 or 1 µM NH-3. Stimulation with T3 alone increased migration distance significantly to 1181.6 ± 7.4 µm (121.1 ± 0.6% of control) compared with 975.6 ± 7.4 µm in the controls (Figure 3A). In contrast, NH-3 inhibited migration of hNPCs to 753.2 ± 7.2 µm, (78.2 ± 1.8% of controls). Coadministration of BDE-47 or BDE-99 and T3 rescued the inhibitory effects of PBDEs completely; the cells migrated over a distance of 1107.4 ± 8.4 µm (113.5 ± 1.2% of control; BDE-47) and 1101.2 ± 18.6 µm (113.8 ± 2.6% of control; BDE-99). In contrast, cotreatment of PBDEs with NH-3 did not have an additive effect, indicating that these substances inhibit migration through an identical mechanism.

To address the question of whether endocrine disruption of the TH system is also responsible for PBDE-induced changes in differentiation, we analyzed nestin expression 7 days after cotreatment with PBDEs and T3 or NH-3. T3 rescued the PBDE-induced cellular increase in nestin expression, whereas NH-3 showed no additive effects in combination with PBDEs (Figure 3B). These results support the notion that PBDEs delay neural differentiation by interfering with cellular THR signaling.

**PBDEs do not influence calcium signaling.** We treated neurospheres for 1 week with 10 µM BDE-47 or -99. Subsequently, we induced differentiation under ongoing PBDE exposure. After 24 hr, we stimulated neurospheres with 1 mM ATP or 500 µM ACh to induce calcium signaling. ATP caused a [Ca2+]i increase in 94.7 ± 4.1% of all cells with a maximal amplitude of 1.5 ± 0.1, whereas ACh caused a [Ca2+]i elevation in 29.2 ± 3.6% of all cells with an amplitude of 1.32 ± 0.0. However, BDE-47 and BDE-99 did not change number of responding cells or amplitude of response (Figure 4).

**PBDEs accumulate in hNPCs.** Exposure of hNPCs to 1 µM 14C-BDE-47 for 7 days resulted in a cellular concentration of 61.16 ± 6.34 µM, which equals an accumulation factor of 60. Only 2% of 14C-BDE-47 remained in the media, indicating that 91% of 14C-BDE-47 was bound to the culture dish [see Supplemental Material, Figure 4 (doi:10.1289/ehp.0901435)].
Discussion

Human exposure to brominated flame retardants is of concern because PBDEs impair neurodevelopment in animals, rising concentrations of these compounds are found in human tissues, and nothing is known about their developmentally neurotoxic effects in humans (Costa et al. 2008). Moreover, the mechanisms by which PBDEs interfere with brain development are not known. To shed light onto the effects caused by PBDE exposure in human developing brain cells, we studied their effects on the development of hNPCs in vitro. These cells are primary human fetal neuroprogenitors and grow as three-dimensional, complex cellular systems, called neurospheres, in culture. Recently, we have established several end points for DNT testing in such neurospheres—proliferation, migration, differentiation, and apoptosis—by employing end-point–specific controls (Moors et al. 2007, 2009). We showed that this neurosphere system is able to reveal exogenously induced disturbances in these basic processes of brain development. In the present study, we applied this novel testing method to unravel the DNT potential of PBDEs for such developing human cells.

PBDEs (0.1–10 µM) are not cytotoxic for proliferating or differentiating hNPCs over a period of 2 weeks, as we demonstrated by different, independent methods [see Supplemental Material, Figures 1 and 2 (doi:10.1289/ehp.0901435)]. In contrast to our findings, the technical PBDE mixture DE-71 (> 20 µM) caused cell death in rat cerebellar granule cells (Reistad et al. 2006), and BDE-99 (> 25 µM) induced cytotoxicity in human astrocytoma cells (Madia et al. 2004). BDE-47 was reported to cause cell death in hippocampal neurons (41.2 µM), human neuroblastoma cells (> 5 µM), and human fetal liver hematopoietic cells (> 50 µM) (He et al. 2008a, 2008b; Shao et al. 2008). Moreover, the higher brominated congener BDE-209 (> 10 µM) was toxic to human HepG2 hepatoma cells (Hu et al. 2007). The cause of cytotoxicity in all these different cell models was induction of apoptosis. Giordano et al. (2008) demonstrated that DE-71 exposure induces oxidative stress. This production of reactive oxygen species is responsible for DE-71–induced apoptosis of rat cerebellar granule neurons (CGN), as indicated by intracellular glutathione (GSH) content, which is a most important determinant of CGN susceptibility to DE-71 neurotoxicity. Moreover, transgenic rat neuron/astrocyte cocultures with proficient versus deficient GSH synthesis support these findings: Astrocytes rich in GSH protected neurons against DE-71–induced neurotoxicity, whereas astrocytes poor in GSH content did not (Giordano et al. 2009). Protection of neurons against PBDE-induced cytotoxicity by the presence of astrocytes is thus the probable reason for differentiated hNPC insensitivity toward PBDE-dependent

Figure 2. PBDEs inhibit differentiation of hNPCs. (A) Representative photomicrographs of hNPCs after 7 days of differentiation. Cells were stained with antibodies against β III tubulin (βIIIITub+) for neurons and O4+ for oligodendrocytes. Cell nuclei were counterstained with Hoechst. Bars, 50 µm. (B) Quantification of immunostaining after PBDE treatment. All data are mean ± SE of three independent experiments (five spheres/experiment). *p ≤ 0.05.
cell death, whereas proliferating precursors are known to possess better defense mechanisms than do postmitotic neural cells (Madhavan et al. 2006). Moreover, such human coculture systems, such as differentiated neurospheres, where the three major cell types of the brain are present in “physiological” ratios, seem to be superior in vitro methods for assessing hazards of chemicals to humans compared with simple monolayer cell lines.

Neurosphere proliferation assessed by monitoring of sphere diameter (Moores et al. 2009) was also not affected by presence of BDE-47 or -99 [see Supplemental Material, Figure 2 (doi:10.1289/ehp.0901435)]. This is in agreement with results from a T-SCREEN assay (Gutleb et al. 2005), a functional assay based on T3-dependent cell proliferation of the rat GH3 pituitary tumor cell line, where also no effects of these two congeners on proliferation were observed (Hamers et al. 2006). In contrast, one of the hydroxylated BDE-47 metabolites, 2-OH-BDE-47 (5–10 µM), inhibited proliferation of the H295R adrenocortical carcinoma cell line (Song et al. 2009). However, this concentration of reactive metabolite causing an antiproliferative effect in these cells is high, and the researchers did not investigate effects of the parent compound. Inhibition of proliferation by BDE-47 was also seen in 5L rat hepatoma cells (Wahl et al. 2008). However, the researchers demonstrated that arylhydrocarbon receptor (AhR) activation by the BDE-47 contaminant 1,2,3,7,8-pentabromodibenzo-furan was responsible for the effects on proliferation, rather than BDE-47 itself. Highly purified BDE-47 does not stimulate the AhR (Peters et al. 2004). This supports our data because PBDEs used in the present study are contaminant-free. Increased proliferation was observed in DE-71-treated MCF-7 breast cancer cells. This stimulation was estrogen receptor dependent, so DE-71 acts as an endocrine disruptor in this estrogen receptor–positive cell line (Merceado-Feliciano and Bigby 2008). Hence, interaction of PBDEs with cell proliferation seems to be congener and cell type specific. So far, all data available on this topic have been obtained in tumor cells. This is, to our knowledge, the first report employing normal human cells or human stem/progenitor cells for determining effects of PBDEs on cell proliferation.

In contrast to proliferation, both investigated PBDE congeners inhibit migration and differentiation of hNPCs significantly in a concentration-dependent manner (Figures 1 and 2). Consequences of PBDE exposure for cell migration have not been investigated so far in any cell type in vivo or in vitro, so this is the first report showing that these chemicals have the ability to interfere with human progenitor cell motility. However, a recent proteomics study by Alm et al. (2008) suggests that PBDE exposure might cause disturbances in cell motility also in vivo. In that study, a single dose of BDE-99 given on mouse postnatal day 10 caused changes in brain protein expression after 24 hr, and one-third of those proteins were related to the cytoskeleton, including actin. The importance of the actin cytoskeleton for neuronal migration has been reviewed extensively (Luo 2002), leaving room for the speculation that PBDEs might interfere with migration through alteration of cytoskeleton-related protein expression.

Similar to PBDE effects on neural migration, to our knowledge, consequences of PBDE exposure for neural differentiation have not been studied so far. Therefore, this is the first report showing that this group of flame retardants can directly interfere with birth of neurons and oligodendrocytes in this human in vivo model. Interference of BDE-47 with neuronal differentiation was also suggested in the fathead minnow because this congener reduced basic transcription element–binding protein (BTEB) expression in their brains (Lema et al. 2008). BTEB is known to be involved in neural differentiation in rodents (Denver et al. 1999). Moreover, BDE-99 altered protein expression of growth-associated protein-43 and brain-derived neurotrophic
PBDEs disrupt human neural development in vitro

During normal development, neural migration and maturation of neural and glial cells are guided by TH (Alvarez-Dolado et al., 1999; Wong and Leung 2001). Therefore, hypothyroidism during development causes a large number of neuroanatomical and behavioral effects (Haddow et al., 1999; Schalock et al., 1977; Zoeller and Crofton, 2005). Because of similar neurobehavioral alterations observed after PBDE exposure in rodents, endocrine disruption of the TH system by PBDEs has been studied intensively. Hypothyroidism of dams and/or offspring was found in a variety of studies after pre- or postnatal exposure [reviewed by Costa et al. (2008)]. This reduction in serum thyroxine (T4) or T3 levels is thought to be caused by induction of the phase II enzyme UDP-glucuronosyl transferase, causing accelerated TH metabolism (Zhou et al., 2002), and by preventing TH from binding to its plasma transport protein transthyretin (Meerts et al., 2000). However, behavioral toxicity of BDE-47 without alterations in T4 and T3 levels was also observed, suggesting that PBDEs cause toxicity by a mechanism beyond changes in body TH homeostasis (Gee and Moser, 2008; Gee et al., 2008). These studies might be explained by the data generated in our experiments because the two PBDE congeners BDE-47 and -99 directly disturb migration and delay differentiation of hNPCs in vitro by endocrine disruption of cellular TH signaling. We confirmed this by two observations: a) PBDE actions are completely antagonized by cotreatment of neurospheres with T3 and b) simultaneous administration of PBDE and the THR antagonist N3-3 did not cause an additive effect. Although NH-3 binds to THRα as well as THRβ, it has a higher affinity to THRβ (Nguyen et al., 2002). Because inhibition of THRα leads to decreased proliferation of avian neurogenic precursors (Lezoualh et al., 1995; but PBDEs do not interfere with hNPC proliferation), and the induction of THRβ induces neural differentiation (Jones et al., 2003; Lebel et al., 1994; and PBDEs disturb neural differentiation of hNPCs), it is likely that PBDEs interfere with THRβ signaling of hNPCs. However, reporter gene analyses in THRα and β overexpressing Chinese hamster ovary cells revealed that neither PBDE congener acted as agonist or antagonist of THRα or THRβ. One possible reason for discrepancies between our study and results in the overexpression system might be that PBDEs act via disturbance of recruitment of THR cofactors. In primary cells, receptors, cofactors, and responsive elements are present at a fine-tuned equilibrium, which is not the case in transfected cells, which overexpress only certain elements of the cellular machinery. That nuclear hormone receptor cofactors might be crucial in endocrine disruption by polyhalogenated aromatic compounds is discussed in our previous work (Fritsche et al., 2005), in which we found that the noncovalent PCB-118 induced oligodendrocyte differentiation in hNPCs. That in vivo work represented the finding in vivo that Aroclor treatment led to an increased expression of TH-dependent genes such as RC3/neurogranin and myelin basic protein in fetal rat brains (Zoeller et al., 2000). To our knowledge, an equivalent rodent study has not yet been performed with PBDEs. Only in the fathead minnow, TH disruption on the basis of THR-dependent gene expression was observed after BDE-47 exposure (Lema et al., 2008). Thus, this is the first work showing that PBDEs can directly interfere with cellular TH signaling in human neural cells.

Besides endocrine disruption, we also investigated whether PBDEs disturb calcium homeostasis. Calcium signaling is a key player in developmental processes (Ciccolini et al., 2003; Greer and Greenberg, 2008), and BDE-47 disturbs calcium homeostasis in rat PC12 pheochromocytoma cells after 20 min of exposure (Dingemans et al., 2008). BDE-47 exerts similar short-term effects on hNPCs (Gassmann K, Krause G, Dingemans M, Schreiber T, Abel J, Bergman A, et al., unpublished observations). To test whether long-term exposure (1 week) to PBDEs also influences calcium signaling and thus contributes to the developmentally neurotoxic effects of PBDEs in hNPC, we measured calcium signaling in PBDE treated hNPCs stimulated with ATP or ACh. Neither BDE-47 nor BDE-99 influenced the response of the cells toward these stimuli, indicating that they do not alter expression of proteins involved in Ca2+ flux. Recently, Viberg (2009) showed that BDE-203 and BDE-206 increase Ca2+/calmodulin-dependent protein kinase (CaMKII) expression in mouse hippocampus. Whether PBDEs interfere with downstream targets of calcium signaling in hNPCs, such as CaMKII or calcineurin, has to be further elucidated.

In summary, BDE-47 and BDE-99 disturb neural migration and differentiation in a human in vitro model for brain development by disruption of cellular TH signaling. The question is now how the lowest observed effect levels from this study relate to actual human PBDE exposure. Therefore, we measured intracellular PBDE concentrations by employing 14C-BDE-47. Because medium concentration-dependent intracellular PBDE accumulation in vitro follows a linear kinetic (Mundy et al., 2004) and neurosphere material is limited, we measured only 1 μM 14C-BDE-47 medium concentration. After 7 days of differentiation, PBDE accumulation is approximately 60-fold. These data support other in vitro data where PBDEs accumulate up to 100-fold in neuronal cells (Mundy et al., 2004). It also reflects PBDE accumulation in postnatal day 10 and 19 mouse brains after 7 days in vitro (~20-~140-fold) that we calculated in a study of Viberg et al. (2003). PBDE exposure of human infants through breast milk is up to 4,000 ng/kg/day (Jones-Otazo et al., 2005). Assuming an average molecular weight of 500 g/mol for PBDEs, this equals an exposure of 8 nM. Taking into account that there is a 60-fold increase in tissue concentration of PBDEs in our human in vitro system and up to a 140-fold increase in brain tissue in mice after oral exposure in vivo (Viberg et al., 2003), infant exposure could result in a brain concentration of 0.5–1.1 μM. Considering that 0.1 μM BDE-99 (~6 μM tissue concentration) decreases neuronal differentiation by approximately 40% (Figure 2), current PBDE exposure levels are likely to be of concern for human health.

Assessing subtle changes in human IQ or behavior in epidemiologic studies is not trivial and needs large numbers of study subjects. Such investigations are needed to reveal whether PBDEs as a hazard identified in this study actually pose a risk for human brain development in vivo.

REFERENCES

Alm H, Kultima K, Schatz B, Nilsson A, Andreu PE, Fex-Svenningsen A, et al. 2008. Exposure to brominated flame retardant PBDE-99 affects cytoskeletal protein expression in the neonatal mouse cerebral cortex. Neurotoxicology 29:628–637.

Alvarez-Dolado M, Ruiz M, Del Rio JA, Alcantara S, Burgaya F, Sheldon M, et al., 1999. Thyroid hormone regulates reelin and dabl expression during brain development. J Neurosci 19:6979–6983.

Binder DK, Scharfman HE. 2004. Brain-derived neurotrophic factor. Growth Factors 22:123–131.

Ciccolini F, Collins TJ, Sudhoelter J, Lipp P, Berridge MJ, Bootman MD. 2003. Local and global spontaneous calcium events regulate neurite outgrowth and onset of GABAergic phenotype during neural precursor differentiation. J Neurosci 23:103–111.

Costa LG, Giordano G, Tagliaterra S, Caglieri A, Mutti A. 2008.
Polybrominated diphenyl ether (PBDE) flame retardants: environmental exposure, human body burden and potential adverse health effects. Acta Biochim Biophys Sin 37:192–173.

Denver RJ, Uffelout L, Furling D, Kobayashi A, Fujiyama I, Puyimurtar J. 1999. Basic transcription element-binding protein for a novel thyroid hormone-regulated gene in the developing central nervous system. Evidence for a role in neurite outgrowth. J Biol Chem 274:3212–32134.

Dingemans MM, de Groot A, van Kleef RG, Bergman A, van den Burg M, Vliekberg H, et al. 2008. Hydroxylation increases the neurotoxic potential of BDE-47 to affect eicosoic and calcium homeostasis in PC12 cells. Environ Health Perspect 116:637–643.

Doucet J, Tague B, Arnold DL, Cooke GM, Hayward S, Gooder CM. 2009. Persistent organic pollutants in human fetal liver and placenta from Greater Montreal, Quebec: a longitudinal study from 1998 through 2006. Environ Health Perspect 117:605–610.

Fischer D, Hooper K, Anathanasiadou M,athanassiadis B, Bergman A. 2006. Children show highest levels of polybrominated diphenyl ethers in a California family of four: a case study. Environ Health Perspect 114:1581–1586.

Fritsche E, Clene JE, Nguyen NH, Scanlan A, Abel J. 2007. Polychlorinated biphenyls disturb differentiation of normal human neural progenitor cells: clue for involvement of thyroid hormone receptors. Environ Health Perspect 115:1031–1036.

Fritsche E, Schaefer C, Calles B, Besmans T, Berenhausen T, Wurm M et al. 2007. Lightening up the UV response by identification of arylhydrocarbon receptor as a cyto- plasmatic receptor for vitamin D3. Proc Natl Acad Sci USA 104:8851–8856.

Gee JR, Hedges JM, Maser VC. 2008. Lack of alterations in thyroid hormones following exposure to polybrominated diphenyl ethers (PBDEs) and toxic organ burden development in mice. Drug Chem Toxicol 31:245–254.

Gee JR, Maser VC. 2008. Acute postnatal exposure to brominated diphenyl ether 47 alters neurotoxicity and alters motor activity in mice. Neurotoxicol Teratol 30:79–87.

Giordano G, Rufford N, McManus T, Giordano G, Fattori V, Vitalone A, Branchi I, Capone F et al. 2009. Mouse cerebellar Purkinje cells in vitro. Neurotoxicology 30:325–329.

Greer PL, Greenberg ME. 2006. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuro Rev 13:548–560.

Gutleb AC, Meerts IATM, Bergsma JH, Schriks M, Murk AJ. 2009. Mouse cerebellar Purkinje cells in vitro. Neurotoxicology 30:325–329.

Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J et al. 1999. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341:549–555.

Hamers T, Kamstra JH, Sonneveld E, Archbold JA, Berg M, Bijker WP et al. 2008. Polybrominated diphenyl ether flame retardants in the urban environment. J Urban Health 85:151–1520.

Sandewall A, Papke A, Young TP, Lung KC, Sjodin A et al. 2004. Different levels of polybrominated diphenyl ethers (PBDEs) and chlorinated compounds in breast milk from two U.K. Regions. Environ Health Perspect 112:1096–1098.

Lebel JM, Dussault JH, Hu DC, Hui Y, Yang FX. 2007. Apoptosis induction by a beta 1 thyroid receptor inducer in neuro-2a cells. Proc Natl Acad Sci USA 94:2644–2648.

Lema SC, Dickey JT, Schultz IR, Swanson P. 2008. Dietary exposure to 2,4,4'-tetrabromodiphenyl ether (PBDE-47) alters thyroid status and thyroid hormone-regulated gene transcription in the pituitary and brain. Environ Health Perspect 116:1994–1999.

Lezoualc'h F, Seugnet I, Monnier AL, Gysdalde J, Behr JP, Demenezes BA. 1995. Inhibition of neurogenic precursor proliferation by antisense alpha thyroid hormone receptor oligonucleotides. J Biol Chem 270:12100–12108.

Luo L. 2002. Actin cytoskeleton regulation in neuronal morphogenesis and its structural plasticity. Annu Rev Cell Dev Biol 18:601–635.

Madsen V, Dureid V, Dureid J. 2006. Increased "vigilance" of antioxidant mechanisms in neural stem cells potentiates their capabilities to resist oxidative stress. Stem Cells 24:2110–2119.

Madiya F, Giordano G, Fattori V, Vitalone A, Branchi I, Capone F et al. 2004. Differential in vitro neurotoxicity of the flame retardant polybrominated diphenyl ethers (PBDE-98 and of the PCB Aroclor 1254) in human astrocytoma cells. Toxicol Lett 154:11–21.

Madinay A, Abdin NR, Abapong A, Bigg T, Rames C. 2008. Polybrominated diphenyl ethers in maternal and fetal blood samples, Environ Health Perspect 117:1249–1252.

Meiers IAM, van Zonden J, Luijks EAC, van Leeuwen-Bol I, Marsh G, Jakobsson E et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Mercado-Feliciano L, Bigsby RM. 2008. The polybrominated diphenyl ether mixture DE-71 is mildly estrogenic. Environ Health Perspect 116:605–611.

Moors M, Clene JE, Abel J, Fritsche E. 2007. ERK-dependent and -independent pathways trigger human neural progenitor cell migration. Toxicol Appl Pharmacol 221:537–547.

Morland KB, Landrigan PJ, Sjodin A, Gobeille AK, Jones RS, Winkel J, et al. 2004. Evaluation of the arylhydrocarbon receptor as a cyto-plasmatic target for ultraviolet B radiation. Proc Natl Acad Sci USA 101:7999–8004.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.

Morris G, Jakobsson E, et al. 2000. Potent competitive interactions of some polybrominated flame retardants and related compounds with human transhlerytin in vitro. Toxicol Sci 56:95–104.